{'fraction_non_alphanumeric': 0.037429249589191166, 'fraction_numerical': 0.0224575497535147, 'mean_word_length': 4.905973689885702, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment

The syndecan (Sdc) family is comprised of four members of cell surface molecules (Sdc-1 to 4) with different biological functions. Syndecan-3 (Sdc-3) is known to be mainly expressed in the brain and nervous tissue and plays a key role in development, cell adhesion, and migration. Recent studies point to important roles for Sdc-3 in inflammatory disease, but the patterns of expression and significance of Sdc-3 in cancer remains unexplored. Here we show that Sdc-3 expression is upregulated on several cancer types, especially in solid tumors that are known to be hypoxic. The Cancer Genome Atlas program (TCGA) data demonstrated that Sdc-3 expression in the tumor microenvironment positively correlates with a hypoxia gene signature. To confirm a potential cause-effect, we performed experiments with tumor cell lines showing increased expression upon in vitro exposure to 1% oxygen or dimethyloxalylglycine, an inhibitor of prolyl hydroxylases, indicating that Sdc-3 expression is promoted by hypoxia inducible factors (HIFs). HIF-1α was responsible for this upregulation as confirmed by CRISPR-engineered tumor cells. Using single-cell RNA sequencing data of melanoma patients, we show that Sdc-3 is expressed on tumor associated macrophages, cancer cells, and endothelial cells. Syndecan-3 expression positively correlated with a macrophage gene signature across several TCGA cancer types. In vitro experiments demonstrated that hypoxia (1% oxygen) or treatment with IFN-γ stimulate Sdc-3 expression on RAW-264.7 derived macrophages, linking Sdc-3 expression to a proinflammatory response. Syndecan-3 expression correlates with a better patient overall survival in hypoxic melanoma tumors.

The syndecan (Sdc) family is comprised of four members of cell surface molecules (Sdc-1 to 4) with different biological functions. Syndecan-3 (Sdc-3) is known to be mainly expressed in the brain and nervous tissue and plays a key role in development, cell adhesion, and migration. Recent studies point to important roles for Sdc-3 in inflammatory disease, but the patterns of expression and significance of Sdc-3 in cancer remains unexplored. Here we show that Sdc-3 expression is upregulated on several cancer types, especially in solid tumors that are known to be hypoxic. The Cancer Genome Atlas program (TCGA) data demonstrated that Sdc-3 expression in the tumor microenvironment positively correlates with a hypoxia gene signature. To confirm a potential cause-effect, we performed experiments with tumor cell lines showing increased expression upon in vitro exposure to 1% oxygen or dimethyloxalylglycine, an inhibitor of prolyl hydroxylases, indicating that Sdc-3 expression is promoted by hypoxia inducible factors (HIFs). HIF-1α was responsible for this upregulation as confirmed by CRISPR-engineered tumor cells. Using single-cell RNA sequencing data of melanoma patients, we show that Sdc-3 is expressed on tumor associated macrophages, cancer cells, and endothelial cells. Syndecan-3 expression positively correlated with a macrophage gene signature across several TCGA cancer types. In vitro experiments demonstrated that hypoxia (1% oxygen) or treatment with IFN-γ stimulate Sdc-3 expression on RAW-264.7 derived macrophages, linking Sdc-3 expression to a proinflammatory response. Syndecan-3 expression correlates with a better patient overall survival in hypoxic melanoma tumors.

INTRODUCTION
In the last decade, syndecans (Sdc) have attracted attention in cancer research since they are markedly dysregulated in the tumor microenvironment (TME) (1)(2)(3)(4). Syndecans are an evolutionary conserved family of small type I transmembrane proteoglycans that are involved in the organization and assembly of extracellular matrix (ECM) (5,6). They consist of a protein core to which heparan sulfate chains are covalently attached. The Sdc family is comprised of four members of cell surface molecules (Sdc-1 to 4) with different biological functions in development, health and disease. They can act as receptors for cytokines, chemokines, morphogens, and growth factors to regulate different signaling pathways (7,8). Thereby Sdc can affect many physiological and pathological processes, including cancer and immunity (5,(9)(10)(11).
Syndecans interact with integrins and growth factor receptors to modulate cell signaling and the ECM, potentially having an impact on tumor progression as suggested by previous studies focused on Sdc-1, Sdc-2, and Sdc-4 (12).
A common feature of all types of solid tumors is an imbalance between cancer cell proliferation and blood supply, which results in hypoxia. The hypoxic response in cells is mediated by the family of hypoxia inducible factor (HIF) transcription factors, which play an integral role in the metabolic changes that drive cellular adaptation to low oxygen availability. In response to hypoxia, a large number of target genes involved in cell growth, metabolism, metastasis, and immunity are activated in cancer cells (30)(31)(32). Hypoxia also modulates the fate and function of different immune populations, including T cells and macrophages (33), and the organization of the ECM that influences their migration and infiltration (34).
Macrophages are abundant in the TME and preferentially accumulate within tumor hypoxic regions (35). Due to their plasticity, they can polarize into pro-inflammatory and antitumor or into anti-inflammatory and pro-tumor agents. Thus, the interaction between cancer cells and tumor-associated macrophages (TAMs) within the hypoxic TME is one of the major features that can dictate the tumor malignancy and progression (36). Indeed, their infiltration has been associated with poor prognosis and therapy resistance in several malignancies (37).
Current state-of-the-art immunotherapies are only effective in a fraction of patients, and several combinatorial approaches have recently failed in the clinic, resulting in an urgent medical need in several cancer types (38). In this context, further knowledge on Sdc-3 regulation and its biological significance in the TME could contribute to the development of new immunotherapies that may widen the spectrum of patients who benefit from these treatments.
In this study, we have found that expression of Sdc-3 is dysregulated in several cancer types and expressed in cancer cells and macrophages, as a result of limited oxygenation in the TME. Syndecan-3 expression correlates with markers of hot tumors such as gamma interferon (IFN-γ), and its expression can predict a better patient overall survival (OS).

Gene Expression on Human Tumors
We selected 21 tumors from The Cancer Genome Atlas program (TCGA) database presenting a significant dysregulation on the expression of Sdc-3 or Sdc-4 between malignant versus normal or adjacent tissue on Gepia 2. 1 The normalized raw data for the gene expression on each tumor and associated normal tissue (TCGA TARGET GTEx dataset) was downloaded through the UCSC Xena browser (39) in log 2 (norm_count + 1) format. The number of tumors and normal or adjacent tissue samples considered in each cancer type are described in Supplementary  Table 1. Statistical analyses were performed using GraphPad Prism version 8.0.

Expression of SDC3 or SDC4 Genes on Human Cell Lines
We obtained the normalized gene expression for these two genes from Iorio et al. (40). A total of 1,018 human cell lines were ordered by the expression level of SDC3 or SDC4 genes. We selected and plotted the top 100 cell lines expressing the highest levels of SDC3 or SDC4 in each case, grouped by representative tissue origin.

SDC3 and SDC4 Gene Expression Across Human Normal Tissues and Stromal Cells
Data corresponding to normal tissue and stromal cells (mean and SD) were collected from the GeneAtlas U133A (41) and Primary Cell Atlas (42) datasets, respectively, through the BioGPS portal. 2 Correlations Between SDC3 or SDC4 and Gene Signatures Spearman correlation analyses between SDC3 or SDC4 and the two different gene signatures used in this study were performed in Gepia 2. The hypoxia signature was defined by Ye et al. (43) and includes the following genes: ACOT7, ADM, ALDOA, CDKN3, ENO1, LDHA, MIF, MRPS17, NDRG1, P4HA1, PGAM1, SLC2A1, TPI1, TUBB6, and VEGFA). The macrophage signature consisted of a set of 92 genes defined by Tirosh et al. (44).

Correlations Between SDC3 or SDC4 and Other Genes
We performed Spearman and Pearson correlation analyses between SDC3 or SDC4 and other genes (IL4, IFNG, CD274, CD8A, or HIF1A). For that purpose, we downloaded the normalized RSEM log 2 (x + 1) data for each TCGA cohort analyzed through the UCSC Xena browser.
Evaluation of SDC3 and SDC4 Gene Expression in the TME Single-cell RNA sequencing data (scRNA-seq) of 19 melanoma tumors were obtained from Tirosh et al. (44). Raw data were processed by SeqGeq version 1.6.0 (FlowJo) and normalized to counts per million (CPMs). We used the cell type specific genesignatures provided by the authors to cluster the immune and tumor cell populations in the TME. We assessed the relative expression of SDC3 and SDC4 within each stromal and tumor cell population, including B cells, cancer associated fibroblasts (CAFs), CD4 + and CD8 + T cells, endothelial cells, tumor associated macrophages (TAMs), and malignant cells.

Cell Culture
Cell lines were obtained from the American Type Culture Collection (ATCC) and cultured according to standard mammalian tissue culture protocols and sterile technique. The murine RAW-264.7 macrophages (ATCC #TIB-71) were cultured in DMEM (Gibco #41966), CT26 cells from mice (ATCC #CRL-2638) were cultured in RPMI medium 1640 GlutaMAX (Gibco #61870044). All media was supplemented with 10% FBS and 1% Penicillin-Streptomycin. All cells were tested for mycoplasma before performing the experiments using the MycoAlert mycoplasma detection kit (Lonza #LT27-221) following manufacturer's instructions. For M1 polarization of RAW-264.7 cells, 300.000 cells/well were seeded in a 6-well plate with 100 ng/mL of IFN-γ (Biolegend #575304) and for M2 polarization, cells were co-cultured with 100 ng/mL of IL-4 (Biolegend #574304). Hypoxia cultures were performed at 1% oxygen and 5% CO 2 in an In Vivo2 400 hypoxic station (Ruskinn Technologies).

Knockout of HIF1A Gene in CT26 Cell Line via CRISPR/Cas9
We generated HIF-1α knockout CT26 murine cells (HIF1-KO) using TrueGuide CRISPR single guide RNAs (sgRNAs) targeting the first exon of the Hif1a gene (sgRNA sequence: uuucuucucguucucgccgc) and the Cas9 nuclease 2NLS (Synthego). RNP-complexes (1.3:1 sgRNA to Cas9 ratio) were introduced in the cells using Lipofectamine CRISPRMAX Cas9 Transfection reagent (ThermoFisher #CMAX00001) and following the CRISPR Editing of Immortalized Cell Lines with RNPs Using Lipofection protocol by Synthego. Transfected cells were cultured in Opti-MEM Reduced Serum Medium (ThermoFisher #31985062) for eight hours and then in RPMI 1640 Medium GlutaMAX (ThermoFisher #61870044) supplemented with 10% FBS and 1% Penicillin-Streptomycin. Seventy-two hours after transfection a limiting dilution (1 cell/mL) was carried out in a 96-well plate followed by clonal expansion. The knockout of Hif1a was checked by Sanger DNA sequencing (StabVida) using primers flanking the sgRNA target region. The HIF1-KO presented a 72 bp deletion affecting the first seven aminoacids of the protein. The deletion was confirmed by quantitative PCR (qPCR) using primers that hybridize within the affected 72 bp region to check the absence of amplification (Supplementary Table 2).

Quantitative PCR
Total RNA was purified using the NucleoSpin RNA kit (Macherey-Nagel #740955.250), diluted in 50 µL of molecular grade water, and quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized by reverse transcription from 250 nG-1µG of purified RNA with the M-MLV Reverse Transcriptase (Thermo Fisher Scientific #28025-013) and Random Primers (Thermo Fisher Scientific #58875) in a final reaction volume of 20 µL. The qPCR reactions were conducted in triplicate on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) from 1 µL of cDNA using the PerfeCTa SYBR Green SuperMix reagent (Quantabio #95056-500) and gene-specific primers (Supplementary Table 2). After an initial denaturation at 95 • C for 3 min, samples were subjected to 40 cycles of denaturation at 95 • C for 15 s, annealing at 60 • C for 60 s, and extension at 72 • C for 60 s. Data were analyzed using the QuantStudio software version 1.3 (Thermo Fisher Scientific). The relative quantification in gene expression was determined using the 2 − Ct method. The Rplp0 gene (also known as 36b4), coding for the ribosomal protein large P0, was used as an internal control to normalize the data.

Expression of Sdc-3 and Sdc-4 Is Significantly Dysregulated in Several Cancer Types
First, we checked SDC3 and SDC4 gene expression levels on malignant and healthy tissue on several types of cancer on the TCGA database (Supplementary Table 1). Figure 1 shows the tumor types that exhibited a significant upregulation, and to lower extent downregulation, of Sdc-3 ( Figure 1A) and Sdc-4 ( Figure 1B) levels based on the ratio of expression on malignant versus normal or adjacent tissue. Focusing on the different tumor types, testicular germ cell tumors (TGCT), skin cutaneous melanoma (SKCM), and diffuse large B-cell lymphoma (DLBC) shown the highest ratio for Sdc-3 ( Figure 1C), while thyroid carcinoma (THCA), ovarian serous cystadenocarcinoma (OV), and DLBC were the highest for Sdc-4 ( Figure 1D). We also studied the levels of expression of Sdc-3 and Sdc-4 on human tumor cell lines representative of different tissue origin from a publicly available dataset (40). In general, the levels of expression of Sdc-4 were higher than Sdc-3 (Figures 1E,F). Syndecan-4 (Sdc-4) expression was also higher than that of Sdc-3 in healthy tissues analyzed from the BioGPS database (Supplementary Figure 1). This analysis also shown that the expression of Sdc-3 (Supplementary Figure 1A) on healthy tissue is confined to spinal cord and brain, as previously described (13,14), while the expression of Sdc-4 (Supplementary Figure 1B) is broader. In a similar fashion to healthy tissue, the expression of Sdc-4 was more homogeneous across the different malignant cell lines (Figure 1F), while the expression of Sdc-3 was mostly enriched in skin cutaneous melanoma (SKCM) cell lines (Figure 1E), in contrast to its low expression in normal skin (Supplementary Figure 1A).

Expression of Sdc-3 and Sdc-4 Correlates With a Hypoxia Signature in Several Cancer Types
Given that the majority of cancer types that shown a significant positive ratio of expression of Sdc-3 and Sdc-4 on malignant versus normal or adjacent tissue are solid tumors (Figures 1A,B), and solid tumors are known to be hypoxic, we interrogated the data for potential correlations between SDC3 or SDC4 genes and a hypoxia signature comprised of 15 genes including LDHA, VEGFA, and others (see section "Materials and Methods"). We found that SDC3 (Figure 2A) and SDC4 (Figure 2B) positively correlated with the expression of the hypoxia signature on several solid tumor types, based on an analysis of the TCGA database. Skin melanoma, the solid tumor type with the highest ratio of expression of Sdc-3 on malignant versus normal tissue (Figures 1A,C), shown a positive correlation with the hypoxia signature for both SDC3 (Figures 2A,C) and SDC4 (Figures 2B,C), while DLBC, a non-solid tumor, presented no significant correlation (Figures 2A-C). Other tumor types with a significant correlation with the hypoxia signature were thymoma (THYM) and THCA for SDC3, and TGCT and pancreatic adenocarcinoma (PAAD) for SDC4 ( Figure 2C). To further explore their expression patterns on hypoxic tumors, we stratified the data on quartiles according to the normalized level of expression of the hypoxia gene signature. As can be seen in Figure 2D, Sdc-3 expression increased with hypoxia levels in SKCM and THCA, and Sdc-4 in SKCM, TGCT, and PAAD.

Sdc-3 and Sdc-4 Are Expressed in Tumor and Stromal Cell Populations in the TME
We investigated which stromal cell types express Sdc-3 and Sdc-4 by examining the Primary Cell Atlas dataset on BioGPS. Syndecan-3 was mostly expressed by monocyte-derived macrophages, and to lower extent on lymphatic endothelium cells and skin fibroblasts ( Figure 3A). Syndecan-4 shown a similar pattern, but with higher expression on skin fibroblasts than that of Sdc-3 ( Figure 3B). No Sdc-3 or Sdc-4 gene expression was detected on B cells or any type of CD4+ or CD8+ T cells (naïve, effector, and central memory) (Figures 3A,B). In order to examine the expression of Sdc-3 and Sdc-4 in the TME, we analyzed single-cell RNA sequencing (scRNA-seq) data from melanoma patients, which was the solid tumor type with the highest ratio of expression of Sdc-3 on malignant/normal tissue based on TCGA database. We defined malignant and stromal components of the TME by established gene signatures to characterize tumor cells, TAMs, CD4+ and CD8+ T cells, B cells, and CAFs ( Figure 3C). SDC3 and SDC4 genes expression levels were the highest on melanoma cells and were also present on macrophages and endothelial cells but absent on B and T cells. Syndecan-4 expression was higher on CAFs than that of Sdc-3 ( Figure 3C). Together, the expression patterns found in the melanoma TME by scRNA-seq are in accordance with those from the Primary Cell Atlas dataset (Figures 3A,B). Interestingly, the expression of Sdc-3 on TAMs was higher than the expression of Sdc-4. To further explore this finding in other cancer types, we performed correlations between a macrophage gene signature panel comprised of 92 genes and SDC3 (Figure 3D) or SDC4 (Figure 3E) genes based on TCGA database. We found a significant positive correlation between the macrophage gene signature and both genes across different tumor types, especially for Sdc-3.

Hypoxia Upregulates Sdc-3 Expression on Tumor Cells on a HIF-1α Dependent Mechanism
In order to study the influence of oxygenation on the expression of Sdc on malignant cells, we cultured the mouse tumor cell line CT26 under normoxia (21% oxygen) or hypoxia (1% oxygen) for 24 h and performed a qPCR. Figure 4A shows that hypoxia induced the transcription of both Sdc3 and Sdc4 genes. We then checked if the HIF molecular pathway was responsible for the observed phenomenon by culturing CT26 tumor cells under normoxia with increasing doses of dimethyloxalylglycine (DMOG), a chemical inhibitor of prolyl and asparaginyl hydroxylases. DMOG prevents HIF-1α degradation, leading to its stabilization and an increase of its transcriptional activity. Figure 4B shows that treatment with DMOG increased the expression of Sdc-3 (left panel) and Sdc-4 (right panel) on a dose dependent manner, suggesting that HIF is involved in the transcriptional control of both genes under hypoxia. To further characterize this response, we examined the putative mouse and human promoters of Sdc-3 where we found several predicted hypoxia response elements (HREs) (Figure 4C). This pointed to a potential role of HIF on the direct regulation of Sdc-3 expression under hypoxia. To confirm this hypothesis, we generated a HIF1-KO via CRISPR/Cas9. The knockout clone presented a 72 bp frameshift deletion that was revealed by Sanger sequencing (Supplementary Figure 2A) and qPCR using primers targeting the deleted region ( Figure 4D, left panel). HIF-1α knockout CT26 cells failed to upregulate known HIF-1α target genes (Pgk1 and Vegfa) when subjected to hypoxia culture (Supplementary Figure 2B), confirming that our knockout model lacks functional HIF-1α protein. Accordingly, HIF1-KO tumor cells did not present HIF-1α protein in the nucleus after 4 h incubation under hypoxia (Supplementary Figure 2C), demonstrating that the generated cell line is suitable for the interrogation of the potential role of HIF-1α in the hypoxic upregulation of Sdc-3. As can be seen on Figure 4D (right panel), HIF1-KO tumor cells failed to upregulate the expression of Sdc-3 under hypoxia as opposed to the wild type (WT) tumor cells.

Hypoxia and IFN-γ Drives Sdc-3 Expression on Tumor Associated Macrophages
In addition to tumor cells, we identified TAMs as the main stromal compartment expressing Sdc-3 in the TME based on scRNA-seq data from melanoma patients ( Figure 3C). We interrogated macrophages derived from murine RAW-264.7 cells in vitro for Sdc-3 gene and protein expression when cultured in the presence of increasing doses of DMOG or under normoxia (21% oxygen) versus hypoxia (1% oxygen) (Figures 5A-E).
Both increasing doses of DMOG and hypoxia induced the expression of Sdc-3 on macrophages at the RNA (Figures 5A,C, respectively) and protein (Figures 5B,D, respectively) levels. We also checked the influence of pro-inflammatory (IFN-γ) and antiinflammatory (IL-4) cytokines on the expression of Sdc3 gene ( Figure 5C). Gamma interferon, but not IL-4, induced a strong  upregulation of Sdc-3 under normoxia (27-fold) and hypoxia (36-fold) at RNA level ( Figure 5C). This upregulation was confirmed at the protein level by flow cytometry (Figures 5D,E). These findings are further supported by the fact that IFN-γ, but not IL-4, induces the stabilization of HIF-1α at the protein level, as previously described by Takeda et al. (45). Moreover, Sdc-3 positively correlated with the expression of IFNG but not IL4 genes across the majority of TCGA tumors analyzed (Supplementary Table 3), as opposed to Sdc-4 that did not shown a broad correlation (Supplementary Table 4). Syndecan-3 also correlated with genes related to the IFN-γ pathway, such as CD274 and CD8A.

Sdc-3 Expression Correlates With a Better Overall Survival on Hypoxic Melanoma Tumors
We investigated the potential prognostic value of Sdc-3 expression on SKCM patients by analyzing OS data on the TCGA database. Figure 6A shows that different levels of expression of Frontiers in Immunology | www.frontiersin.org the hypoxia gene signature does not impact patient OS. High expression of IFNG gene predicts a significant increase of OS ( Figure 6B). Interestingly, when stratifying the cohort based on the high or low expression of the hypoxia signature genes, the increase of the OS based on IFNG gene expression was only significant on the most hypoxic tumors (Figure 6B). On a similar fashion, high Sdc-3 expression significantly correlated with a better OS in melanoma ( Figure 6C). This difference was only present in highly hypoxic tumors, suggesting that Sdc-3 expression is associated with hypoxia and a proinflammatory immune response, leading to better patient OS in melanoma.

DISCUSSION
Here we show for the first time that hypoxia induces Sdc-3 expression on a HIF-1α dependent mechanism. Syndecan-3 is expressed on tumor cells, macrophages, and endothelial cells in the TME (Figure 7). These results suggest that Sdc-3 may have a functional role in solid tumors with limited oxygen availability. Another member of the Sdc family, Sdc-4, has previously been described as a HIF-1α target in other cell types (46). Here we also show that Sdc-4 correlates with a hypoxia signature and gets upregulated on tumor cells upon inhibition of PHDs. The pattern of expression of Sdc-4 in tumor infiltrating cells is similar to that of Sdc-3, with the exception of a higher expression on CAFs. On the contrary, we have not observed that Sdc-1 or Sdc-2 expression is controlled by hypoxia. We found a broad upregulation of the expression of Sdc-3 in several tumor types. Because solid tumors are known to be hypoxic, we tested the hypothesis if the expression of Sdc-3 was influenced by hypoxia. Experiments performed with DMOG demonstrated that the inhibition of PHDs directly control the expression of Sdc-3, and we confirmed this finding with a HIF-1α deficient tumor cell line, and by the identification of several HREs on the Sdc-3 promoter. Taken together, our results indicate that Sdc-3 expression is hypoxia-sensitive and depends on HIF-1α activity in tumor cells.
Next, we investigated the expression of Sdc-3 in other cell types present in the TME. Apart from cancer cells, endothelial cells and macrophages were identified as Sdc-3 expressing cell populations. Expression of Sdc-3 by endothelial cells has been previously reported (21) in the context of inflammatory disease (47) but its potential role on tumor angiogenesis is still largely unexplored (14). Importantly, Sdc-3 expression correlated with a macrophage gene signature in several cancer types. We found that TAMs infiltrating hypoxic tumors have significant expression of Sdc-3. Hypoxia directly induces Sdc-3 expression on macrophages. Interestingly, treatment with IFN-γ, but not IL-4, promotes Sdc-3 expression on macrophages. These findings are in line with the fact that IFN-γ stabilizes HIF-1α in macrophages (45).
Induction of Sdc-3 expression by IFN-γ indicates that Sdc-3 could be a marker of hot tumors. Hot tumors are characterized by a high degree of cytotoxic T cell infiltration that are the main source of IFN-γ. IFN-γ promotes tumor immune responses and limits cancer cell growth, but can also induce the expression of immune checkpoint molecules (i.e., PD-L1) or other immunosuppressive factors. In general, hot tumors have a better patient prognosis and predict the response to T cell checkpoint inhibition (48). The impact of tumor hypoxia in patient survival and response to therapies is less clear. Hypoxia inducible factor is known to promote a malignant tumor cell phenotype, metabolic alterations, and immunosuppressive pathways (i.e., adenosine pathway), but also to promote antitumor immune responses (33,49).
Focusing on melanoma, a tumor that is considered immunogenic and in which expression of IFN-γ has a significant prognostic value, we show that expression of a hypoxia gene signature does not have an impact on patients OS. However, high expression of Sdc-3 on hypoxic tumors correlates with a better patient survival.
The impact of gene expression and function of hypoxia target genes in the TME is becoming a complex area of research with the potential of unraveling novel therapeutic targets. Little is known about the function of Sdc-3 in cancer progression and its influence on the immune response. Given the expression of Sdc-3 on endothelial cells and its role in remodeling the ECM, Sdc-3 might have an impact on immune cell infiltration, which could be modulated by therapeutic intervention. Moreover, the strong upregulation of Sdc-3 on tumor versus normal tissue indicates that this molecule could be exploited as a tumor-associated antigen in approaches based on cell therapy or antibody drug conjugates. Therefore, our findings support further investigation on the role of Sdc-3 in the TME to ascertain its potential use as a novel therapeutic target.

DATA AVAILABILITY STATEMENT
All datasets presented in this study are included in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS
EP-F planned and executed experiments and wrote the manuscript. LE-M, SL, and AB executed experiments and performed flow cytometry analyses. AG, BJ-L, and AA-V performed data analyses. AP conceived and supervised the project and wrote the manuscript. All authors reviewed the manuscript.